
About Organovo
Organovo is a publicly listed company based in San Diego (United States) founded in 2007. Functional three-dimensional human tissues are developed using 3D bioprinting technology. Organovo has raised $6.67 million across 13 funding rounds from investors including NIH, HHS and National Science Foundation. Organovo offers products and services including 3D Bioprinted Tissues and Bioprinting Technology. Its focus areas include High Tech, 3D Printing, Applications and Healthcare. Its legal entity is Organovo, Inc. Its competitors include Dimension Inx, Prellis Biologics and FluidForm Bio; 2 of its 3 listed competitors have raised funding.
Company details
Organovo has developed ExVive technology to design and create functional, three-dimensional human tissues for medical research and therapeutic applications with its proprietary scaffold-free 3D bioprinting technology. It works on the principle of interaction between drops of liquid, which come together to form multicellular aggregates, similarly mammalian cells form aggregates without the use of any component. The company calls these cellular aggregates as Bio-Ink, which would form intact tissues.It offers services in 3D Human Liver Tissue Testing, Human Liver Tissue Testing performance, and 3D Human Kidney Tissue Testing. It partners with academic institutes focusing on a single therapeutic area to develop disease modeling and therapeutics using 3D Bioprinting. The company has received orphan drug designation from the US FDA for its 3D bioprinted liver therapeutic tissue for alpha-1 antitrypsin deficiency.
- Headquarters San Diego, United States
- Stage Public
- SectorsTechnology
- Website organovo.com
- Social LinkedIn X Facebook YouTube
- Legal Name Organovo, Inc.
- Total Equity Funding$6.67M (USD)
in 13 rounds
- Latest Funding Round$1.66M (USD), Grant
Jul 2017
- InvestorsNIH
& 2 more
Products & Services of Organovo
Organovo offers a comprehensive portfolio of products and services, including 3D Bioprinted Tissues and Bioprinting Technology.
Human tissues for drug testing and research applications.
Tools for creating 3D tissues in biomedical studies.
Apps and channels of Organovo
its YouTube channel Organovo Holdings, Inc. has 1.16K subscribers and 16 videos.
Videos from Organovo
The most watched videos on Organovo's YouTube channel, Organovo Holdings, Inc. (1.16K subscribers). Click a video to play it here.
More on Organovo Holdings, Inc..
Funding Insights of Organovo
Organovo has successfully raised a total of $6.67M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $1.66 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.67M
- Total Rounds 13
- Last Round Grant β $1.66M
- First Round $5M
(Jun 2005)
- Investors Count 3
Latest 10 of 13 funding rounds of Organovo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $1.66M | Grant | β | β | |
| Apr 2012 | $290,053 | Grant | β | β | |
| Mar 2012 | $15.2M | Post-IPO | β | β | β |
| Mar 2012 | $290,053 | Grant | β | β | |
| Nov 2011 | $3.49M | Series A | β | β | β |
| Sep 2010 | $125,114 | Grant | β | β | |
| Aug 2010 | $125,114 | Grant | β | β | |
| Jun 2010 | $178,250 | Seed | β | β | β |
| Sep 2009 | $142,511 | Grant | β | β | |
| Aug 2009 | $142,511 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Organovo
Organovo has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Organovo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Organovo
10 people are tracked at Organovo (1 in leadership, 9 in team).
| Name | Role | Group |
|---|---|---|
Cari Rosette | Director Drug Discovery | Leadership |
Curtis Tyree | Svp, Strategy And Business Development | Team |
Eric Benson | Lead Engineer | Team |
Haylee Aidnik | Scientist Ii, Histology | Team |
Nicholas Pavlick | Corporate Controller | Team |
Cole Toohey | Research Associate II | Team |
Rachel Dudum | Scientist II | Team |
Payton Olson | Senior Research Associate | Team |
Kyle Austin | Laboratory Assistant | Team |
Alexander Le | Senior Research Associate | Team |
Complete people profiles for Organovo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Organovo
4 dated milestones of Organovo across 12 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $5.0M.
- Founded Organovo is founded.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $1.7M.
Competitors of Organovo
Organovo has 3 listed competitors in our database, 2 of them funded. They include Dimension Inx, Prellis Biologics and FluidForm Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dimensioninx.com | 2017 | Chicago, United States | $15.42M | 3D biomaterials are provided for regenerative medicine applications. | ||
| prellisbio.com | 2016 | San Francisco, United States | $69.85M | 22 | Provider of 3D bioprinting technology to build human tissues for drug development | |
| fluidformbio.com | 2017 | Waltham, United States | 19 | 3D bioprinting solutions for engineered tissues are developed. |
Detailed competitors of Organovo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Organovo
The website of Organovo (organovo.com) receives about 4K visits a month.
- Monthly visits4K
▼ 1.7% vs previous month
Websites whose visitors overlap most with Organovo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ddw-online.com | ddw-online.com | 100% | #514,775 | β | |
| biospectrumindia.com | 100% | #482,715 | View details | ||
| nature.com | 97% | 33.6M | #1,922 | View details | |
utdr.utoledo.edu | utdr.utoledo.edu | 81% | β | ||
news.sciencemag.org | news.sciencemag.org | 77% | #2,923,793 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Organovo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in 3D Printing & Scanning Services
3 companies that operate in the same segment as Organovo (3D Printing & Scanning Services) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Platform for on-demand distributed manufacturing and prototyping is provided. | 2013 | Gaithersburg, Maryland, United States | USD 200.44 M | USD 686.63 M | 1,090 | |
Provider of cloud and AI-based virtual tour solutions for construction professionals | 2011 | Sunnyvale, California, United States | USD 163.18 M | |||
Hover is recognized for providing construction and renovation software solutions. | 2011 | San Francisco, California, United States | USD 142.3 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Organovo
Complete news archive for Organovo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organovo
Organovo was founded in 2007.
Organovo is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Organovo is a funded company, having raised a total of $6.67M across 13 funding rounds to date. The company's 1st funding round was a Grant of $142.51K, raised on Jun 2005.
Organovo has developed ExVive technology to design and create functional, three-dimensional human tissues for medical research and therapeutic applications with its proprietary scaffold-free 3D bioprinting technology. It works on the principle of interaction between drops of liquid, which come together to form multicellular aggregates, similarly mammalian cells form aggregates without the use of any component. The company calls these cellular aggregates as Bio-Ink, which would form intact tissues.It offers services in 3D Human Liver Tissue Testing, Human Liver Tissue Testing performance, and 3D Human Kidney Tissue Testing. It partners with academic institutes focusing on a single therapeutic area to develop disease modeling and therapeutics using 3D Bioprinting. The company has received orphan drug designation from the US FDA for its 3D bioprinted liver therapeutic tissue for alpha-1 antitrypsin deficiency.
Organovo's top competitors include FluidForm Bio, Prellis Biologics and Dimension Inx.
Organovo offers 3D Bioprinted Tissues and Bioprinting Technology.
Organovo has 3 investors. Key investors include NIH, HHS, and National Science Foundation.
Organovo operates through Organovo, Inc..
